Klaus Kopka

List of Publications by Year
in descending order

225 papers	12,980 citations	28274 55 h-index	26613 107 g-index
248 all docs	248 docs citations	248 times ranked	8167 citing authors

#	Article	IF	Citations
1	Towards Optimized Bioavailability of 99mTc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity. Molecular Imaging and Biology, 2022, 24, 434-443.	2.6	3
2	Non-Invasive Assessment of Locally Overexpressed Human Adenosine 2A Receptors in the Heart of Transgenic Mice. International Journal of Molecular Sciences, 2022, 23, 1025.	4.1	1
3	Experimental techniques to study proteinâ€"surfactant interactions: New insights into competitive adsorptions via drop subphase and interface exchange. Advances in Colloid and Interface Science, 2022, 301, 102601.	14.7	18
4	A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer. Pharmaceuticals, 2022, 15, 267.	3.8	1
5	Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [18F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain. Pharmaceuticals, 2022, 15, 324.	3.8	0
6	Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives. Pharmaceuticals, 2022, 15, 432.	3.8	7
7	Automated radiosynthesis of the adenosine A _{2A} receptorâ€targeting radiotracer [¹⁸ F]FLUDA. Journal of Labelled Compounds and Radiopharmaceuticals, 2022, , .	1.0	1
8	â€œClickableâ€•Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals. Journal of Medicinal Chemistry, 2022, 65, 710-733.	6.4	13
9	Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends. Frontiers in Nuclear Medicine, 2022, 2, .	1.2	3
10	Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors. Molecular Pharmaceutics, 2022, 19, 2231-2247.	4.6	5
11	Quantitation of the A2A Adenosine Receptor Density in the Striatum of Mice and Pigs with [18F]FLUDA by Positron Emission Tomography. Pharmaceuticals, 2022, 15, 516.	3.8	3
12	Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. Pharmaceuticals, 2022, 15, 747.	3.8	18
13	Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of mIDH1 Mutant Tumours. Molecules, 2022, 27, 3766.	3.8	2
14	Structure-Based Design, Optimization, and Development of [¹⁸F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET. Journal of Medicinal Chemistry, 2022, 65, 9034-9049.	6.4	10
15	Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 143-151.	6.4	25
16	Development of the First Potential Nonpeptidic Positron Emission Tomography Tracer for the Imaging of CCR2 Receptors. ChemMedChem, 2021, 16, 640-645.	3.2	5
17	On the consensus nomenclature rules for radiopharmaceutical chemistry â€" Reconsideration of radiochemical conversion. Nuclear Medicine and Biology, 2021, 93, 19-21.	0.6	43
18	Highlight selection of radiochemistry and radiopharmacy developments by editorial board (Januaryâ€"June 2020). EJNMMI Radiopharmacy and Chemistry, 2021, 6, 5.	3.9	1

#	Article	IF	Citations
19	The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2057-2058.	6.4	23
20	Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies. Cancer Research, 2021, 81, 2234-2245.	0.9	11
21	Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer. Pharmaceuticals, 2021, 14, 188.	3.8	5
22	Development of an ¹⁸F-Labeled Irreversible Inhibitor of Transglutaminase 2 as Radiometric Tool for Quantitative Expression Profiling in Cells and Tissues. Journal of Medicinal Chemistry, 2021, 64, 3462-3478.	6.4	16
23	Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 13.	3.9	1
24	Predicting the Risk of Metastases by PSMA-PET/CTâ€"Evaluation of 335 Men with Treatment-NaÃ¯ve Prostate Carcinoma. Cancers, 2021, 13, 1508.	3.7	8
25	Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules. Journal of Nuclear Medicine, 2021, 62, 1461-1467.	5.0	9
26	Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMAâ€"A Proof of Concept Study. Cancers, 2021, 13, 1974.	3.7	25
27	Development of bispecific theranostic ligand targeting the prostate specific membrane antigen (PSMA) and gastrin releasing peptide (GRPR) receptor. Nuclear Medicine and Biology, 2021, 96-97, S29-S30.	0.6	0
28	The radiolabeling of silicon rhodamines for multimodal PET/ SPECT- and NIR optical imaging. Nuclear Medicine and Biology, 2021, 96-97, S81.	0.6	0
29	131Ba as a promising SPECT-diagnostic match for 223/224Radium. Nuclear Medicine and Biology, 2021, 96-97, S95.	0.6	0
30	11C-Methionine Uptake in the Lactating Human Breast. Clinical Nuclear Medicine, 2021, Publish Ahead of Print, e66-e67.	1.3	0
31	The impact of barium isotopes in radiopharmacy and nuclear medicine â€" From past to presence. Nuclear Medicine and Biology, 2021, 98-99, 59-68.	0.6	15
32	Synthesis and application of a thiol-reactive HBED-type chelator for development of easy-to-produce Ga-radiopharmaceutical kits and imaging probes. Organic and Biomolecular Chemistry, 2021, 19, 1722-1726.	2.8	10
33	Intraindividual comparison of [68ÂGa]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Research, 2021, 11, 109.	2.5	32
34	Radiolabeled Silicon-Rhodamines as Bimodal PET/SPECT-NIR Imaging Agents. Pharmaceuticals, 2021, 14, 1155.	3.8	4
35	Radiolabeled PSMA Inhibitors. Cancers, 2021, 13, 6255.	3.7	22
36	Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. Journal of Nuclear Medicine, 2020, 61, 70-79.	5.0	23

#	Article	IF	Citations
37	Lymph Node Involvement in Treatment-NaÃ¯ve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management. Journal of Nuclear Medicine, 2020, 61, 46-50.	5.0	26
38	Response Prediction of ¹⁷⁷Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. Journal of Nuclear Medicine, 2020, 61, 689-695.	5.0	39
39	18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 592-602.	6.4	26
40	Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging. Pharmaceuticals, 2020, 13, 272.	3.8	25
41	Live-cell imaging with Aspergillus fumigatus-specific fluorescent siderophore conjugates. Scientific Reports, 2020, 10, 15519.	3.3	13
42	Development of PSMA-1007-Related Series of ¹⁸F-Labeled Glu-Ureido-Type PSMA Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 10897-10907.	6.4	18
43	Deuteration versus ethylation â€“ strategies to improve the metabolic fate of an ¹⁸F-labeled celecoxib derivative. RSC Advances, 2020, 10, 38601-38611.	3.6	6
44	Rhenium and technetium-complexed silicon rhodamines as near-infrared imaging probes for bimodal SPECT- and optical imaging. Dalton Transactions, 2020, 49, 7294-7298.	3.3	7
45	Synthesis, characterization and evaluation of 68Ga labelled monomeric and dimeric quinazoline derivatives of the HBED-CC chelator targeting the epidermal growth factor receptor. Bioorganic Chemistry, 2020, 100, 103855.	4.1	12
46	Subâ€10â€…nm Radiolabeled Barium Sulfate Nanoparticles as Carriers for Theranostic Applications and Targeted Alpha Therapy. ChemistryOpen, 2020, 9, 797-805.	1.9	16
47	Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov. Pharmaceuticals, 2020, 13, 12.	3.8	34
48	Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 18.	3.9	11
49	68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 28.	3.9	19
50	Radiopharmaceutical Sciences. , 2020, , 49-191.		2
51	18F-Labeled Small-Molecule and Low-Molecular-Weight PET Tracers for the Noninvasive Detection of Cancer. Recent Results in Cancer Research, 2020, 216, 283-318.	1.8	3
52	Detection Efficacy of ¹⁸F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine, 2019, 60, 362-368.	5.0	238
53	⁶⁸Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. Journal of Nuclear Medicine, 2019, 60, 234-240.	5.0	49
54	EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2536-2544.	6.4	265

#	Article	IF	Citations
55	LutatheraÂ®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals, 2019, 12, 114.	3.8	218
56	Synthesis of a dihalogenated pyridinyl silicon rhodamine for mitochondrial imaging by a halogen dance rearrangement. Beilstein Journal of Organic Chemistry, 2019, 15, 2333-2343.	2.2	6
57	A Multifunctional HBED-Type Chelator with Dual Conjugation Capabilities for Radiopharmaceutical Development. Synlett, 2019, 30, 1795-1798.	1.8	7
58	A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR. OncoImmunology, 2019, 8, 1659095.	4.6	23
59	HBED-NN: A Bifunctional Chelator for Constructing Radiopharmaceuticals. Journal of Organic Chemistry, 2019, 84, 7501-7508.	3.2	15
60	DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay. Mutagenesis, 2019, 34, 239-244.	2.6	12
61	Bispecific radioligands targeting prostateâ€specific membrane antigen and gastrinâ€releasing peptide receptors on the surface of prostate cancer cells. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 510-522.	1.0	7
62	Impact of ¹⁸F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice. Journal of Nuclear Medicine, 2019, 60, 1594-1599.	5.0	15
63	Designing tracers for PET imaging of the urokinaseâ€type plasminogen activator receptor from a cyclic uPAâ€derived peptide: first in vitro evaluations. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 483-494.	1.0	1
64	A new approach to silicon rhodamines by Suzukiâ€“Miyaura coupling â€“ scope and limitations. Beilstein Journal of Organic Chemistry, 2019, 15, 2569-2576.	2.2	4
65	Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors. Cancer Research, 2019, 79, 841-852.	0.9	33
66	Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing â€œthe leadâ€• into PSMA-targeted alpha therapy?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1081-1091.	6.4	77
67	Biochemical Recurrence of Prostate Cancer: Initial Results with [¹⁸F]PSMA-1007 PET/CT. Journal of Nuclear Medicine, 2018, 59, 632-635.	5.0	55
68	A Convenient Synthesis for HBED-CC-tris(tert-butyl ester). Synlett, 2018, 29, 1239-1243.	1.8	9
69	Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1179-1187.	6.4	26
70	Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging. EJNMMI Research, 2018, 8, 28.	2.5	17
71	Monomeric and Dimeric ⁶⁸Ga-Labeled Bombesin Analogues for Positron Emission Tomography (PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors (GRPrs). Journal of Medicinal Chemistry, 2018, 61, 2062-2074.	6.4	27
72	Cytochrome b 5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b 5 /P450 reductase null (HBRN) mice. Archives of Toxicology, 2018, 92, 1625-1638.	4.2	26

#	Article	IF	Citations
73	68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 904-912.	6.4	34
74	Intraindividual Comparison of ¹⁸F-PSMA-1007 and ¹⁸F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. Journal of Nuclear Medicine, 2018, 59, 1076-1080.	5.0	140
75	[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. Clinical Genitourinary Cancer, 2018, 16, 111-113.	1.9	4
76	Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, 103-105.	1.9	4
77	Simultaneous whole-body 18Fâ€"PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 340-347.	6.4	32
78	PSMA-11â€"Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 639-645.	5.0	89
79	Repeated ¹⁷⁷Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. Journal of Nuclear Medicine, 2018, 59, 459-465.	5.0	68
80	Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on Î³-fluorinated Î±-sulfonylaminohydroxamic acid. EJNMMI Radiopharmacy and Chemistry, 2018, 3, 10.	3.9	7
81	Imaging and radiotherapy for recurrent prostate cancer: An evolutionary partnership. Radiotherapy and Oncology, 2018, 129, 387-388.	0.6	1
82	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2045-2054.	6.4	116
83	Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 351-359.	1.0	9
84	18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e497-e499.	1.9	47
85	The Clinical Impact of Additional Late PET/CT Imaging with ⁶⁸Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 750-755.	5.0	105
86	68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1014-1024.	6.4	589
87	⁶⁸Ga or¹⁸F for Prostate Cancer Imaging?. Journal of Nuclear Medicine, 2017, 58, 687-688.	5.0	105
88	Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1258-1268.	6.4	425
89	Intraindividual Comparison of ¹⁸F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. Journal of Nuclear Medicine, 2017, 58, 1805-1810.	5.0	91
90	Radiolabeled Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitors: (Radio)Syntheses and in Vitro and First in Vivo Evaluation. Journal of Medicinal Chemistry, 2017, 60, 307-321.	6.4	19

#	Article	IF	Citations
91	Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1636-1646.	6.4	17
92	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 776-787.	6.4	124
93	Improved clinical workflow for simultaneous whole-body PET/MRI using high-resolution CAIPIRINHA-accelerated MR-based attenuation correction. European Journal of Radiology, 2017, 96, 12-20.	2.6	24
94	Glu-Ureidoâ€"Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. Journal of Nuclear Medicine, 2017, 58, 17S-26S.	5.0	111
95	Identification of Ligands and Translation to Clinical Applications. Journal of Nuclear Medicine, 2017, 58, 27S-33S.	5.0	16
96	Comparison of human cytochrome P450 1A1-catalysed oxidation of benzo[a]pyrene in prokaryotic and eukaryotic expression systems. Monatshefte FÃ¼r Chemie, 2017, 148, 1959-1969.	1.8	10
97	Improving the Imaging Contrast of ⁶⁸Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. Bioconjugate Chemistry, 2017, 28, 2485-2492.	3.6	40
98	Reply: PSMA Ligands for Imaging Prostate Cancer: Alternative Labeling by Complex Formation with Al¹⁸F²⁺. Journal of Nuclear Medicine, 2017, 58, 2041-2041.	5.0	1
99	⁶⁸Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1949-1955.	5.0	27
100	Preclinical Evaluation of ¹⁸F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. Journal of Nuclear Medicine, 2017, 58, 425-431.	5.0	186
101	Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 50-62.	6.4	37
102	Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone. Archives of Toxicology, 2017, 91, 1957-1975.	4.2	22
103	F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 678-688.	6.4	421
104	Clinical Translation and First In-Human Use of [⁴⁴Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. Theranostics, 2017, 7, 4359-4369.	10.0	94
105	Syntheses of Radioiodinated Pyrimidine-2,4,6-Triones as Potential Agents for Non-Invasive Imaging of Matrix Metalloproteinases. Pharmaceuticals, 2017, 10, 49.	3.8	7
106	Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. Pharmaceuticals, 2017, 10, 77.	3.8	83
107	Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 168-180.	0.7	19
108	Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI. PLoS ONE, 2017, 12, e0183329.	2.5	53

#	Article	IF	Citations
109	Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas. Radiation Oncology, 2017, 12, 174.	2.7	18
110	Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients. Cancer Imaging, 2017, 17, 30.	2.8	8
111	Role of Radiolabelled Small Molecules Binding to PSMA in Diagnosis and Therapy of Prostate Cancer. , 2017, , 51-58.		1
112	Abstract 3719: Bicyclic peptides for PET imaging of MT1-MMP expressing tumors. , 2017, , .		0
113	Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals. Theranostics, 2016, 6, 1085-1095.	10.0	60
114	68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. Clinical Nuclear Medicine, 2016, 41, e473-e479.	1.3	86
115	Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1400-1406.	6.4	101
116	The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 79S-89S.	5.0	200
117	Future trends in prostate cancer theranostics with PSMA ligands. Clinical and Translational Imaging, 2016, 4, 487-489.	2.1	6
118	Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 405-418.	4.6	72
119	²²⁵Ac-PSMA-617 for PSMA-Targeted Î±-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 1941-1944.	5.0	741
120	NADH:Cytochrome b₅ Reductase and Cytochrome b₅ Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[a]pyrene. Chemical Research in Toxicology, 2016, 29, 1325-1334.	3.3	31
121	Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier. Science Translational Medicine, 2016, 8, 364ra152.	12.4	94
122	Epoxyeicosatrienoic acids (EETs) form adducts with DNA in vitro. Prostaglandins and Other Lipid Mediators, 2016, 123, 63-67.	1.9	1
123	Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1611-1620.	6.4	143
124	Robust augmented reality guidance with fluorescent markers in laparoscopic surgery. International Journal of Computer Assisted Radiology and Surgery, 2016, 11, 899-907.	2.8	29
125	18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1929-1930.	6.4	81
126	The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/â€“) and Trp53(â^'/â^') mice. Archives of Toxicology, 2016, 90, 839-851.	4.2	36

#	Article	IF	Citations
127	68Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1288-1299.	6.4	58
128	PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷Lu-Labeled PSMA-617. Journal of Nuclear Medicine, 2016, 57, 1170-1176.	5.0	475
129	Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: How chemical modifications affect pharmacokinetics and metabolic stability. Nuclear Medicine and Biology, 2016, 43, 424-437.	0.6	9
130	Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1673-1683.	6.4	13
131	Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo. Toxicology, 2016, 344-346, 7-18.	4.2	22
132	Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 1761-1775.	6.4	150
133	Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer. Bioconjugate Chemistry, 2016, 27, 737-751.	3.6	48
134	New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clinical Cancer Research, 2016, 22, 9-15.	7.0	155
135	Positron Emission Tomographyâ€"computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer. European Urology, 2016, 69, 397-399.	1.9	10
136	68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 34-41.	6.4	194
137	Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 70-83.	6.4	148
138	Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 42-51.	6.4	244
139	New matrix metalloproteinase inhibitors based on Î³-fluorinated Î±-aminocarboxylic and Î±-aminohydroxamic acids. Bioorganic and Medicinal Chemistry, 2015, 23, 3809-3818.	3.0	18
140	Synthesis, binding affinity and structureâ€"activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists. Organic and Biomolecular Chemistry, 2015, 13, 2407-2422.	2.8	14
141	PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 293-298.	5.0	100
142	Novel fluorine-18 labeled 5-(1-pyrrolidinylsulfonyl)-7-azaisatin derivatives as potential PET tracers for in vivo imaging of activated caspases in apoptosis. Bioorganic and Medicinal Chemistry, 2015, 23, 5734-5739.	3.0	8
143	Multimodal Imaging Reveals Temporal and Spatial Microglia and Matrix Metalloproteinase Activity after Experimental Stroke. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1711-1721.	4.3	62
144	PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1794-1800.	6.4	109

#	Article	IF	Citations
145	Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 914-920.	5.0	451
146	[177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 987-988.	6.4	155
147	MP53-08 THE DIAGNOSTIC VALUE OF 68 GA-LABELLED PSMA-LIGAND PET/CT IN MEN WITH RECURRENT PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.4	0
148	The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Journal of Nuclear Medicine, 2015, 56, 1697-1705.	5.0	332
149	The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 197-209.	6.4	866
150	Preclinical evaluation of a bispecific lowâ€molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate, 2014, 74, 659-668.	2.3	93
151	Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals, 2014, 7, 779-796.	3.8	323
152	Pharmaceuticalsâ€"Special Issue on Radiopharmaceutical Chemistry between Imaging and Endoradiotherapy. Pharmaceuticals, 2014, 7, 839-849.	3.8	2
153	Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1280-1292.	6.4	319
154	PET/CT studies of multiple myeloma using 18â€‰F-FDG and 18â€‰F-NaF: comparison of distribution patterns and tracersâ€™ pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1343-1353.	6.4	55
155	Mechanistic and high-throughput approaches for the design of molecular imaging probes and targeted therapeutics. Clinical and Translational Imaging, 2014, 2, 33-41.	2.1	1
156	Diverse modifications of the 4-methylphenyl moiety of TAK-779 by late-stage Suzukiâ€"Miyaura cross-coupling. Organic and Biomolecular Chemistry, 2014, 12, 177-186.	2.8	8
157	Synthesis of 7-Halogenated Isatin Sulfonamides: Nonradioactive Counterparts of Caspase-3/-7 Inhibitor-Based Potential Radiopharmaceuticals for Molecular Imaging of Apoptosis. Journal of Medicinal Chemistry, 2014, 57, 9383-9395.	6.4	13
158	Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3â€²-Deoxy-3â€²-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging. Journal of Nuclear Medicine, 2014, 55, 983-988.	5.0	21
159	Influence of 4- or 5-substituents on the pyrrolidine ring of 5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin derivatives onÂtheir inhibitory activities towards caspases-3 and -7. European Journal of Medicinal Chemistry, 2013, 64, 562-578.	5.5	8
160	Inverse 1,2,3-Triazole-1-yl-ethyl Substituted Hydroxamates as Highly Potent Matrix Metalloproteinase Inhibitors: (Radio)synthesis, in Vitro and First in Vivo Evaluation. Journal of Medicinal Chemistry, 2013, 56, 6858-6870.	6.4	34
161	Non-peptidyl 18F-Labelled PET Tracers as Radioindicators for the Noninvasive Detection of Cancer. Recent Results in Cancer Research, 2013, 187, 107-132.	1.8	2
162	Synthesis of new fluorinated, 2-substituted 5-pyrrolidinylsulfonyl isatin derivatives as caspase-3 and caspase-7 inhibitors: Nonradioactive counterparts of putative PET-compatible apoptosis imaging agents. Bioorganic and Medicinal Chemistry, 2013, 21, 2025-2036.	3.0	23

#	Article	IF	Citations
163	Synthesis, 18F-Radiolabeling, and in Vivo Biodistribution Studies of N-Fluorohydroxybutyl Isatin Sulfonamides using Positron Emission Tomography. Journal of Medicinal Chemistry, 2013, 56, 4509-4520.	6.4	11
164	A Closer Look at the Bromineâ€"Lithium Exchange with tert-Butyllithium in an Aryl Sulfonamide Synthesis. Organic Letters, 2013, 15, 2954-2957.	4.6	45
165	Early Assessment of the Efficacy of Temozolomide Chemotherapy in Experimental Glioblastoma Using [18F]FLT-PET Imaging. PLoS ONE, 2013, 8, e67911.	2.5	32
166	Synthesis and in vivo evaluation of an (18)F-labeled glycoconjugate of PD156707 for imaging ETA receptor expression in thyroid carcinoma by positron emission tomography. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 425-36.	1.0	5
167	A New Class of Highly Potent Matrix Metalloproteinase Inhibitors Based on Triazole-Substituted Hydroxamates: (Radio)Synthesis and in Vitro and First in Vivo Evaluation. Journal of Medicinal Chemistry, 2012, 55, 4714-4727.	6.4	43
168	Radiosynthesis of a 68Ga labeled matrix metalloproteinase inhibitor as a potential probe for PET imaging. Applied Radiation and Isotopes, 2012, 70, 1723-1728.	1.5	6
169	Efficient synthesis of a fluorine-18 labeled biotin derivative. Nuclear Medicine and Biology, 2012, 39, 1189-1194.	0.6	6
170	A New Generation of Radiofluorinated Pyrimidine-2,4,6-triones as MMP-Targeted Radiotracers for Positron Emission Tomography. Journal of Medicinal Chemistry, 2012, 55, 223-232.	6.4	49
171	Metabolite Identification of a Radiotracer by Electrochemistry Coupled to Liquid Chromatography with Mass Spectrometric and Radioactivity Detection. Analytical Chemistry, 2011, 83, 5415-5421.	6.5	29
172	Development and Evaluation of Endothelin-A Receptor (Radio)Ligands for Positron Emission Tomography. Journal of Medicinal Chemistry, 2011, 54, 939-948.	6.4	17
173	The MMP inhibitor (R)-2-(N-benzyl-4-(2-[18F]fluoroethoxy)phenylsulphonamido)-N-hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis. Applied Radiation and Isotopes, 2011, 69, 862-868.	1.5	26
174	Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. British Journal of Radiology, 2011, 84, S168-S178.	2.2	2
175	Radiofluorinated Pyrimidineâ€2,4,6â€triones as Molecular Probes for Noninvasive MMPâ€Targeted Imaging. ChemMedChem, 2010, 5, 777-789.	3.2	59
176	Molecular Imaging of Cardiac Sympathetic Innervation by ¹¹C-mHED and PET: From Man to Mouse?. Journal of Nuclear Medicine, 2010, 51, 1269-1276.	5.0	22
177	Synthesis of Geminal Difluorides by Oxidative Desulfurizationâˆ'Difluorination of Alkyl Aryl Thioethers with Halonium Electrophiles in the Presence of Fluorinating Reagents and Its Application for¹⁸F-Radiolabeling. Journal of Organic Chemistry, 2010, 75, 6086-6095.	3.2	15
178	Preclinical evaluation of an 18F-labelled Î²1-adrenoceptor selective radioligand based on ICI 89,406. Nuclear Medicine and Biology, 2010, 37, 517-526.	0.6	12
179	Encapsulating 111In in Nanocontainers for Scintigraphic Imaging: Synthesis, Characterization, and In Vivo Biodistribution. ACS Nano, 2010, 4, 342-348.	14.6	82
180	Biodistribution of a Nonpeptidic Fluorescent Endothelin a Receptor Imaging Probe. Molecular Imaging, 2009, 8, 7290.2009.00003.	1.4	15

#	Article	IF	Citations
181	Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers â€“ A Status Report. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 968-985.	1.7	23
182	Fluorinated isatin derivatives. Part 1: Synthesis of new N-substituted (S)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatins as potent caspase-3 and -7 inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 2680-2688.	3.0	48
183	PET-compatible endothelin receptor radioligands: Synthesis and first in vitro and in vivo studies. Bioorganic and Medicinal Chemistry, 2009, 17, 7197-7208.	3.0	11
184	A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: Radiosynthesis and initial small-animal PET studies. Applied Radiation and Isotopes, 2009, 67, 606-610.	1.5	60
185	Synthesis and Evaluation of a Novel Hydroxamate Based Fluorescent Photoprobe for Imaging of Matrix Metalloproteinases. Bioconjugate Chemistry, 2009, 20, 904-912.	3.6	32
186	Fluorinated Isatin Derivatives. Part 2. New N-Substituted 5-Pyrrolidinylsulfonyl Isatins as Potential Tools for Molecular Imaging of Caspases in Apoptosis. Journal of Medicinal Chemistry, 2009, 52, 3484-3495.	6.4	71
187	Fluorinated isatin derivatives. Part 3. New side-chain fluoro-functionalized pyrrolidinyl sulfonyl isatins as potent caspase-3 and -7 inhibitors. Future Medicinal Chemistry, 2009, 1, 969-989.	2.3	19
188	Non-Invasive Approaches to Visualize the Endothelin Axis In Vivo Using State-of-the-Art Molecular Imaging Modalities. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1580-1595.	2.4	2
189	Are [O-methyl-11C]derivatives of ICI 89,406 Î²1-adrenoceptor selective radioligands suitable for PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 174-185.	6.4	7
190	18F-labelled cardiac PET tracers: selected probes for the molecular imaging of transporters, receptors and proteases. Basic Research in Cardiology, 2008, 103, 131-143.	5.9	11
191	Characterization of 3-[123I]iodo-L-Î±-methyl tyrosine transport in astrocytes of neonatal rats. Journal of Neurochemistry, 2008, 76, 97-104.	3.9	11
192	18Fâ€Labeled PETâ€Tracers for Cardiological Imaging. , 2008, , 85-139.		1
193	Synthesis and Evaluation of a Novel Fluorescent Photoprobe for Imaging Matrix Metalloproteinases. Bioconjugate Chemistry, 2008, 19, 1001-1008.	3.6	51
194	Î²1-Adrenoceptors in Rat Anterior Pituitary May Be Constitutively Active. Inverse Agonism of CGP 20712A on Basal 3â€²,5â€²-Cyclic Adenosine 5â€²-Monophosphate Levels. Endocrinology, 2008, 149, 2391-2402.	2.8	8
195	A Fluorescent Photoprobe for the Imaging of Endothelin Receptors. Bioconjugate Chemistry, 2007, 18, 685-694.	3.6	27
196	Novel Fluorinated Derivatives of the Broad-Spectrum MMP Inhibitors N-Hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as Potential Tools for the Molecular Imaging of Activated MMPs with PET. Journal of Medicinal Chemistry, 2007, 50, 5752-5764.	6.4	68
197	Molecular cardiovascular imaging using scintigraphic methods. European Radiology, 2007, 17, 1422-1432.	4.5	9
198	Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1-8.	6.4	39

#	Article	IF	Citations
199	Synthesis, in vitro pharmacology and biodistribution studies of new PD 156707-derived ETA receptor radioligands. Bioorganic and Medicinal Chemistry, 2006, 14, 1910-1917.	3.0	13
200	5-Pyrrolidinylsulfonyl Isatins as a Potential Tool for the Molecular Imaging of Caspases in Apoptosis. Journal of Medicinal Chemistry, 2006, 49, 6704-6715.	6.4	63
201	Synthesis of an18F-labelled high affinityÎ²1-adrenoceptor PET radioligand based on ICI 89,406. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 177-195.	1.0	11
202	Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET. Current Medicinal Chemistry, 2006, 13, 2819-2838.	2.4	84
203	Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT. Journal of Nuclear Medicine, 2006, 47, 1635-42.	5.0	69
204	Synthesis of (R)- and (S)-[O-methyl-11C]N-[2-[3-(2-cyano-phenoxy)-2-hydroxy-propylamino]-ethyl]-Nâ€²-(4-methoxy-phenyl)-urea as candidate high affinityÎ²1-adrenoceptor PET radioligands. Journal of Labelled Compounds and Radiopharmaceuticals, 2005, 48, 721-733.	1.0	7
205	Non-Invasive Molecular Imaging of β-Adrenoceptors In Vivo: Perspectives for PET-Radioligands. Current Medicinal Chemistry, 2005, 12, 2057-2074.	2.4	30
206	C-5-Disubstituted Barbiturates as Potential Molecular Probes for Noninvasive Matrix Metalloproteinase Imaging. Journal of Medicinal Chemistry, 2005, 48, 3400-3409.	6.4	58
207	Scintigraphic Imaging of Matrix Metalloproteinase Activity in the Arterial Wall In Vivo. Circulation, 2004, 109, 2554-2559.	1.6	211
208	Early Effects of Irradiation on [123I]-IMT and [18F]-FDG Uptake in Rat C6 Glioma Cells. Strahlentherapie Und Onkologie, 2004, 180, 434-441.	2.0	10
209	Synthesis and first in vivo evaluation of new selective high affinity Î²1-adrenoceptor radioligands for SPECT based on ICI 89,406. Bioorganic and Medicinal Chemistry, 2004, 12, 4117-4132.	3.0	14
210	Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nuclear Medicine and Biology, 2004, 31, 257-267.	0.6	72
211	Design of new Î²1-selective adrenoceptor ligands as potential radioligands for in vivo imaging. Bioorganic and Medicinal Chemistry, 2003, 11, 3513-3527.	3.0	26
212	Prognostic Significance of Amino Acid Transport Imaging in Patients with Brain Tumors. Neurosurgery, 2002, 50, 958-965.	1.1	0
213	Prognostic Significance of Amino Acid Transport Imaging in Patients with Brain Tumors. Neurosurgery, 2002, 50, 958-965.	1.1	10
214	Current status and future applications of cardiac receptor imaging with positron emission tomography. Nuclear Medicine Communications, 2002, 23, 113-115.	1.1	9
215	3-[123I]Iodo-L-Î±-methyl tyrosine transport into human fibroblasts and comparison with Ewingâ€™s sarcoma cells. Nuclear Medicine and Biology, 2002, 29, 483-490.	0.6	2
216	Characterization of 3-[123I]iodo-L-Î±-methyl tyrosine ([123I]IMT) transport into human Ewingâ€™s sarcoma cells in vitro. Nuclear Medicine and Biology, 2001, 28, 123-128.	0.6	11

#	Article	IF	Citations
217	Kinetic parameters of 3-[123I]iodo-L-Î±-methyl tyrosine ([123I]IMT) transport in human GOS3 glioma cells. Nuclear Medicine and Biology, 2001, 28, 293-297.	0.6	20
218	Sequential scintigraphic strategy for the differentiation of brain tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 550-558.	6.4	27
219	Kinetics of 3-[123I]iodo-l-Î±-methyltyrosine transport in rat C6 glioma cells. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1274-1278.	2.1	22
220	Kinetics of 3-[. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1274.	2.1	9
221	Ein zweikerniger Vanadium(V)-Komplex mit (Î¼¹)- und (Î¼-Î¼²:Î¼²)-gebundenen Hydrazido(2-)-Liganden / A Dinuclear Vanadium(V) Com plex with (Î¼¹)- and (Î¼-Î¼²:Î¼²)-Bonded Hydrazido(2-) Ligands. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 1996, 51, 1675-1678.	0.7	9
222	Novel radiolabeled silicon rhodamine dyes for bimodal scintigraphic and optical imaging. , 0, , .		1
223	Procedures for the GMP-Compliant Production and Quality Control of [¹⁸F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. , 0, , .		0
224	â€œClickableâ€•albumin binders to modulate pharmacokinetic properties of theranostic radioligands. , 0, , .		0
225	Barium-131 as starting point for the development of radiotheranostic approaches. , 0, , .		0